View Filing Data

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

The table below summarizes significant regulatory and commercialization events and milestones (deferred) capitalized for the compounds included in this collaboration:



	Year Launched			Milestones (Deferred) Capitalized ⁽¹⁾
Product Family	U.S.	Europe	Japan	Year	Amount
Trajenta ⁽²⁾	2011	2011	2011	Cumulative ⁽⁴⁾- all prior to 2017	$	446.4
Jardiance ⁽³⁾	2014	2014	2015	Cumulative ⁽⁴⁾- all prior to 2017	299.5
Basaglar	2016	2015	2015	Cumulative ⁽⁴⁾ - all prior to 2017	(250.0		)

⁽²⁾Jentadueto is included in the Trajenta product family.

⁽³⁾Glyxambi and Synjardyare included in the Jardiance product family.

⁽⁴⁾The cumulative amount represents the total initial amounts that were (deferred) or capitalized from the start of this collaboration through the end of the reporting period.

Bi Compounds

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]



	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Basaglar	$	201.8	$	86.6	$	367.8	$	132.6
Jardiance	147.2		103.2		298.2		177.1
Trajenta	141.7		141.9		282.8		254.9

Erbitux

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

The following table summarizes our revenue recognized with respect to Erbitux:



	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Net product revenue	$	141.1	$	134.4	$	263.3	$	265.7
Collaboration and other revenue	25.3		24.7		52.8		47.8
Revenue	$	166.4	$	159.1	$	316.1	$	313.5

Effient

Restructuring and Related Activities [Abstract]

The following table summarizes our revenue recognized with respect to Effient:



	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Revenue	$	27.9	$	142.9	$	59.5	$	270.7

Asset Impairment, Restructuring, and Other Special Charges (Tables)

6 Months Ended

Jun. 30, 2018

The components of the charges included in asset impairment, restructuring, and other special charges

The components of the charges included in asset impairment, restructuring, and other special charges in our consolidated condensed statements of operations are described below.



	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Severance:
Human pharmaceutical products	$	(24.6	)	$	(1.7	)	$	(24.7	)	$	111.3
Animal health products	(2.7		)	0.7			4.8			56.3
Total severance	(27.3		)	(1.0		)	(19.9		)	167.6
Asset impairment and other special charges - Animal health products	101.7			51.0			172.6			96.3
Total asset impairment, restructuring, and other special charges	$	74.4		$	50.0		$	152.7		$	263.9

Financial Instruments (Tables)

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Schedule of effects of risk-management instruments were recognized in other–net, (income) expense

The following effects of risk-management instruments were recognized in other–net, (income) expense:



	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Fair value hedges:
Effect from hedged fixed-rate debt	$	(19.7	)	$	15.0		$	(74.5	)	$	7.5
Effect from interest rate contracts	19.7			(15.0		)	74.5			(7.5		)
Cash flow hedges:
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	3.7			3.7			7.3			7.4
Net losses on foreign currency exchange contracts not designated as hedging instruments	59.1			25.8			75.7			62.9

Schedule of effective portion of risk-management instruments that was recognized in other comprehensive income (loss)

The effective portion of risk-management instruments that was recognized in other comprehensive income (loss) is as follows:



	Three Months Ended June 30,					Six Months Ended June 30,
	2018		2017			2018		2017
Net investment hedges:
Foreign currency-denominated notes	$	208.5	$	(194.4	)	$	100.8	$	(273.3	)
Cross-currency interest rate swaps	69.1		(51.5		)	37.6		(57.6		)
Cash flow hedges:
Forward-starting interest rate swaps	—		13.0			—		13.0

Summary certain fair value information



					Fair Value Measurements Using
	Carrying Amount		Cost ⁽¹⁾		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Fair Value
June 30, 2018
Cash equivalents	$	5,188.2	$	5,188.2	$	5,188.2	$	—	$	—	$	5,188.2

Short-term investments:
U.S. government and agency securities	$	10.1	$	10.1	$	10.1	$	—	$	—	$	10.1
Corporate debt securities	70.1		70.2		—		70.1		—		70.1
Asset-backed securities	7.8		7.8		—		7.8		—		7.8
Other securities	4.2		4.2		—		4.2		—		4.2
Short-term investments	$	92.2

Noncurrent investments:
U.S. government and agency securities	$	161.9	$	167.9	$	161.9	$	—	$	—	$	161.9
Corporate debt securities	659.5		672.4		—		659.5		—		659.5
Mortgage-backed securities	106.5		110.5		—		106.5		—		106.5
Asset-backed securities	31.8		32.2		—		31.8		—		31.8
Other securities	136.0		39.3		—		—		136.0		136.0
Marketable equity securities	315.7		133.5		315.7		—		—		315.7
Equity investments without readily determinable fair values ⁽²⁾	392.8
Equity method investments ⁽²⁾	255.4
Noncurrent investments	$	2,059.6

December 31, 2017
Cash equivalents	$	4,763.9	$	4,763.9	$	4,712.4	$	51.5	$	—	$	4,763.9

Short-term investments:
U.S. government and agency securities	$	217.8	$	218.2	$	217.8	$	—	$	—	$	217.8
Corporate debt securities	1,182.3		1,183.2		—		1,182.3		—		1,182.3
Asset-backed securities	94.2		94.3		—		94.2		—		94.2
Other securities	3.6		3.6		—		3.6		—		3.6
Short-term investments	$	1,497.9

Noncurrent investments:
U.S. government and agency securities	$	360.0	$	365.0	$	360.0	$	—	$	—	$	360.0
Corporate debt securities	3,464.3		3,473.5		—		3,464.3		—		3,464.3
Mortgage-backed securities	202.4		204.2		—		202.4		—		202.4
Asset-backed securities	653.9		656.0		—		653.9		—		653.9
Other securities	132.1		66.4		—		—		132.1		132.1
Marketable equity securities	281.3		131.0		281.3		—		—		281.3
Cost and equity method investments ⁽²⁾	584.8
Noncurrent investments	$	5,678.8

⁽¹⁾For available-for-sale debt securities, amounts disclosed represent the securities' amortized cost.

Summary certain fair value information, liabilities



				Fair Value Measurements Using
	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)		Fair Value
Short-term commercial paper borrowings
June 30, 2018	$	(2,448.0	)	$	—	$	(2,445.9	)	$	—	$	(2,445.9	)
December 31, 2017	(2,696.8		)	—		(2,690.6		)	—		(2,690.6		)
Long-term debt, including current portion
June 30, 2018	$	(9,771.6	)	$	—	$	(10,063.5	)	$	—	$	(10,063.5	)
December 31, 2017	(10,950.3		)	—		(11,529.9		)	—		(11,529.9		)

Fair value, by balance sheet grouping



				Fair Value Measurements Using
	Carrying Amount			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)			Significant Unobservable Inputs (Level 3)			Fair Value
June 30, 2018
Risk-management instruments:
Interest rate contracts designated as fair value hedges:
Other current liabilities	$	(4.2	)	$	—	$	(4.2	)	$	—		$	(4.2	)
Other noncurrent liabilities	(45.5		)	—		(45.5		)	—			(45.5		)
Cross-currency interest rate contracts designated as net investment hedges:
Other receivables	21.2			—		21.2			—			21.2
Sundry	4.2			—		4.2			—			4.2
Other current liabilities	(20.5		)	—		(20.5		)	—			(20.5		)
Foreign exchange contracts not designated as hedging instruments:
Other receivables	11.8			—		11.8			—			11.8
Other current liabilities	(9.6		)	—		(9.6		)	—			(9.6		)
Contingent consideration liabilities ⁽¹⁾:
Other current liabilities	(123.3		)	—		—			(123.3		)	(123.3		)
Other noncurrent liabilities	(41.1		)	—		—			(41.1		)	(41.1		)

December 31, 2017
Risk-management instruments:
Interest rate contracts designated as fair value hedges:
Other receivables	$	0.8		$	—	$	0.8		$	—		$	0.8
Sundry	35.1			—		35.1			—			35.1
Other current liabilities	(0.2		)	—		(0.2		)	—			(0.2		)
Other noncurrent liabilities	(10.5		)	—		(10.5		)	—			(10.5		)
Cross-currency interest rate contracts designated as net investment hedges:
Other current liabilities	(33.4		)	—		(33.4		)	—			(33.4		)
Other noncurrent liabilities	(26.0		)	—		(26.0		)	—			(26.0		)
Foreign exchange contracts not designated as hedging instruments:
Other receivables	26.8			—		26.8			—			26.8
Other current liabilities	(36.0		)	—		(36.0		)	—			(36.0		)
Contingent consideration liabilities ⁽¹⁾:
Other current liabilities	(208.0		)	—		—			(208.0		)	(208.0		)
Other noncurrent liabilities	(45.2		)	—		—			(45.2		)	(45.2		)

⁽¹⁾Contingent consideration liabilities primarily relate to the Erbitux arrangement with BMS discussed in Note 4.

Summary the contractual maturities of our investments in debt securities measured at fair value

The table below summarizes the contractual maturities of our investments in debt securities measured at fair value as of June 30, 2018:



	Maturities by Period
	Total		Less Than 1 Year		1-5 Years		6-10 Years		More Than 10 Years
Fair value of debt securities	$	1,047.7	$	88.0	$	656.8	$	148.3	$	154.6

Summary of the fair value of available-for-sale securities in an unrealized gain or loss position and the amount of unrealized gains and losses (pretax) in accumulated other comprehensive loss



	June 30, 2018		December 31, 2017
Unrealized gross gains	$	1.8	$	184.7
Unrealized gross losses	25.2		47.5
Fair value of securities in an unrealized gain position	148.0		1,434.2
Fair value of securities in an unrealized loss position	898.0		4,692.8

Summary of the amount of unrealized gains and losses (pretax) recognized in our statement of operations for equity securities

A summary of the unrealized gains and losses (pretax) recognized in our statements of operations for equity securities held as of June 30, 2018 is as follows:

Activity related to our investment portfolio, substantially all of which related to equity and available-for-sale securities, was as follows:



	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Proceeds from sales	$	4,953.8	$	959.0	$	5,546.4	$	2,051.5
Realized gross gains on sales	5.6		22.2		7.7		73.9
Realized gross losses on sales	47.4		1.1		49.0		2.4

Retirement Benefits (Tables)

6 Months Ended

Jun. 30, 2018

Defined Benefit Pension Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]

Schedule of Net Benefit Costs

Net pension and retiree health benefit (income) cost included the following components:



	Defined Benefit Pension Plans
	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Components of net periodic benefit cost:
Service cost	$	77.7		$	86.7		$	158.1		$	165.6
Interest cost	112.0			103.2			224.6			205.6
Expected return on plan assets	(211.2		)	(195.3		)	(423.7		)	(389.3		)
Amortization of prior service cost	1.3			1.5			2.5			2.9
Recognized actuarial loss	91.6			70.4			182.0			143.1
Net periodic benefit cost	$	71.4		$	66.5		$	143.5		$	127.9

Retiree Health Benefit Plans

Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Line Items]

Schedule of Net Benefit Costs



	Retiree Health Benefit Plans
	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Components of net periodic benefit income:
Service cost	$	10.9		$	12.0		$	21.6		$	23.2
Interest cost	13.5			13.4			27.4			26.4
Expected return on plan assets	(43.9		)	(40.1		)	(87.8		)	(80.4		)
Amortization of prior service benefit	(20.4		)	(22.5		)	(40.9		)	(45.0		)
Recognized actuarial loss	2.2			5.1			4.6			9.2
Net periodic benefit income	$	(37.7	)	$	(32.1	)	$	(75.1	)	$	(66.6	)

Other Comprehensive Income (Loss) (Tables)

6 Months Ended

Jun. 30, 2018

Statement of Comprehensive Income [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

The following tables summarize the activity related to each component of other comprehensive income (loss) during the three months ended June 30, 2018 and 2017:



(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)			Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss
Balance at April 1, 2018	$	(850.6	)	$	(51.0	)	$	(4,304.4	)	$	(231.5	)	$	(5,437.5	)

Other comprehensive income (loss) before reclassifications	(820.9		)	65.9			54.5			0.1			(700.4		)
Net amount reclassified from accumulated other comprehensive loss	—			(33.0		)	59.3			2.9			29.2
Net other comprehensive income (loss)	(820.9		)	32.9			113.8			3.0			(671.2		)

Balance at June 30, 2018	$	(1,671.5	)	$	(18.1	)	$	(4,190.6	)	$	(228.5	)	$	(6,108.7	)



(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)			Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss
Balance at April 1, 2017	$	(1,648.7	)	$	179.4		$	(3,349.4	)	$	(208.4	)	$	(5,027.1	)

Other comprehensive income (loss) before reclassifications	299.3			(12.5		)	(37.7		)	8.4			257.5
Net amount reclassified from accumulated other comprehensive loss	—			(13.7		)	38.6			2.4			27.3
Net other comprehensive income (loss)	299.3			(26.2		)	0.9			10.8			284.8

Balance at June 30, 2017 ⁽¹⁾	$	(1,349.4	)	$	153.2		$	(3,348.5	)	$	(197.6	)	$	(4,742.3	)

The following tables summarize the activity related to each component of other comprehensive income (loss) during the six months ended June 30, 2018 and 2017:



(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)			Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss
Balance at January 1, 2018 ⁽²⁾	$	(1,233.4	)	$	113.5		$	(4,340.7	)	$	(234.3	)	$	(5,694.9	)

Reclassification due to adoption of new accounting standard ⁽³⁾	—			(128.9		)	—			—			(128.9		)
Other comprehensive income (loss) before reclassifications	(438.1		)	29.9			32.4			—			(375.8		)
Net amount reclassified from accumulated other comprehensive loss	—			(32.6		)	117.7			5.8			90.9
Net other comprehensive income (loss)	(438.1		)	(2.7		)	150.1			5.8			(284.9		)

Balance at June 30, 2018	$	(1,671.5	)	$	(18.1	)	$	(4,190.6	)	$	(228.5	)	$	(6,108.7	)



(Amounts presented net of taxes)	Foreign Currency Translation Gains (Losses)			Unrealized Net Gains (Losses) on Securities			Defined Benefit Pension and Retiree Health Benefit Plans			Effective Portion of Cash Flow Hedges			Accumulated Other Comprehensive Loss
Balance at January 1, 2017 ⁽²⁾	$	(1,867.3	)	$	224.0		$	(3,371.6	)	$	(210.9	)	$	(5,225.8	)

Other comprehensive income (loss) before reclassifications	517.9			(24.3		)	(54.6		)	8.4			447.4
Net amount reclassified from accumulated other comprehensive loss	—			(46.5		)	77.7			4.9			36.1
Net other comprehensive income (loss)	517.9			(70.8		)	23.1			13.3			483.5

Balance at June 30, 2017 ⁽¹⁾	$	(1,349.4	)	$	153.2		$	(3,348.5	)	$	(197.6	)	$	(4,742.3	)

The tax effects on the net activity related to each component of other comprehensive income (loss) were as follows:



	Three Months Ended June 30,						Six Months Ended June 30,
Tax benefit (expense)	2018			2017			2018			2017
Foreign currency translation gains/losses	$	(58.3	)	$	86.1		$	(18.2	)	$	115.8
Unrealized net gains/losses on securities	(8.9		)	11.5			1.3			29.6
Defined benefit pension and retiree health benefit plans	(23.6		)	(6.1		)	(37.9		)	(14.6		)
Effective portion of cash flow hedges	(0.7		)	(5.8		)	(1.5		)	(7.1		)
Benefit/(provision) for income taxes allocated to other comprehensive income (loss) items	$	(91.5	)	$	85.7		$	(56.3	)	$	123.7

Schedule of Amounts Recognized in Other Comprehensive Income (Loss)

Reclassifications out of accumulated other comprehensive loss were as follows:



Details about Accumulated Other Comprehensive Loss Components	Three Months Ended June 30,						Six Months Ended June 30,						Affected Line Item in the Consolidated Condensed Statements of Operations
	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Amortization of retirement benefit items:
Prior service benefits, net	$	(19.1	)	$	(21.0	)	$	(38.4	)	$	(42.1	)	⁽¹⁾
Actuarial losses, net	93.8			75.5			186.6			152.3			⁽¹⁾
Total before tax	74.7			54.5			148.2			110.2
Tax benefit	(15.4		)	(15.9		)	(30.5		)	(32.5		)	Income taxes
Net of tax	59.3			38.6			117.7			77.7

Unrealized gains/losses on available-for-sale securities:
Realized (gains), losses, net	(41.8		)	(21.1		)	(41.3		)	(71.5		)	Other–net, (income) expense
Tax (benefit) expense	8.8			7.4			8.7			25.0			Income taxes
Net of tax	(33.0		)	(13.7		)	(32.6		)	(46.5		)
Other, net of tax	2.9			2.4			5.8			4.9			Other–net, (income) expense
Total reclassifications for the period (net of tax)	$	29.2		$	27.3		$	90.9		$	36.1

⁽¹⁾These accumulated other comprehensive loss components are included in the computation of net periodic benefit (income) cost (see Note 9).

Other - Net, (Income) Expense (Tables)

6 Months Ended

Jun. 30, 2018

Nonoperating Income (Expense) [Abstract]

Schedule of Other–net, (income) expense

Other–net, (income) expense consisted of the following:



	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Interest expense	$	63.3		$	53.6		$	124.5		$	100.2
Interest income	(41.2		)	(36.9		)	(86.7		)	(69.5		)
Retirement benefit	(54.9		)	(64.3		)	(111.3		)	(127.5		)
Other income	(5.2		)	(12.8		)	(32.0		)	(41.9		)
Other–net, (income) expense	$	(38.0	)	$	(60.4	)	$	(105.5	)	$	(138.7	)

Segment Information (Tables)

6 Months Ended

Jun. 30, 2018

Segment Reporting [Abstract]

Schedule of segment reporting information, by segment



	Six Months Ended June 30,
	2018						2017
	U.S. ⁽¹⁾		Outside U.S.		Total		U.S. ⁽¹⁾		Outside U.S.		Total
Segment revenue—to unaffiliated customers:
Human pharmaceutical products:
Endocrinology:
Humalog	$	968.7	$	592.8	$	1,561.5	$	839.4	$	547.3	$	1,386.8
Trulicity	1,140.6		317.5		1,458.1		677.2		176.0		853.1
Forteo	346.6		401.1		747.8		427.4		366.7		794.2
Humulin	460.4		211.5		671.9		431.9		240.4		672.3
Basaglar	283.2		84.6		367.8		81.5		51.1		132.6
Jardiance	180.6		117.6		298.2		114.6		62.6		177.1
Trajenta	110.9		171.9		282.8		105.8		149.1		254.9
Other Endocrinology	125.4		140.2		265.6		191.2		152.1		343.3
Total Endocrinology	3,616.4		2,037.2		5,653.7		2,869.0		1,745.3		4,614.3

Oncology:
Alimta	526.7		528.9		1,055.5		501.6		521.2		1,022.8
Cyramza	143.7		258.7		402.4		134.9		222.7		357.6
Erbitux	261.3		54.7		316.1		262.2		51.3		313.5
Other Oncology	185.3		107.4		292.7		84.8		64.2		149.0
Total Oncology	1,117.0		949.7		2,066.7		983.5		859.4		1,842.9

Cardiovascular:
Cialis	659.1		375.0		1,034.1		677.7		483.2		1,160.9
Effient	29.2		30.3		59.5		248.0		22.7		270.7
Other Cardiovascular	103.8		64.5		168.3		15.7		62.4		78.0
Total Cardiovascular	792.1		469.8		1,261.9		941.4		568.3		1,509.6

Neuroscience:
Cymbalta	24.8		326.7		351.5		81.2		300.0		381.2
Zyprexa	20.6		230.0		250.6		36.7		251.6		288.3
Strattera	63.9		181.0		244.9		223.9		158.9		382.8
Other Neuroscience	45.7		51.0		96.7		65.2		48.5		113.7
Total Neuroscience	155.0		788.7		943.7		407.0		759.0		1,166.0

Immunology:
Taltz	284.7		81.8		366.5		212.3		23.1		235.4
Other Immunology	1.8		75.2		76.9		—		6.6		6.6
Total Immunology	286.5		157.0		443.4		212.3		29.7		242.0

Other pharmaceuticals	35.7		96.7		132.5		23.9		99.6		123.6
Total human pharmaceutical products	6,002.7		4,499.1		10,501.9		5,437.1		4,061.3		9,498.4
Animal health products	754.0		799.4		1,553.4		820.3		733.8		1,554.2
Revenue	$	6,756.7	$	5,298.6	$	12,055.2	$	6,257.5	$	4,795.1	$	11,052.6

Numbers may not add due to rounding.

⁽¹⁾U.S. revenue includes revenue in Puerto Rico.



	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Segment profits:
Human pharmaceutical products	$	1,720.2		$	1,352.3		$	3,237.0		$	2,523.2
Animal health products	144.5			152.4			299.4			300.7
Total segment profits	$	1,864.6		$	1,504.7		$	3,536.3		$	2,823.9

Reconciliation of total segment profits to consolidated income before taxes:
Segment profits	$	1,864.6		$	1,504.7		$	3,536.3		$	2,823.9
Other profits (losses):
Acquired in-process research and development (Note 3)	(1,624.5		)	—			(1,624.5		)	(857.6		)
Amortization of intangible assets	(152.9		)	(178.1		)	(305.3		)	(354.2		)
Asset impairment, restructuring, and other special charges (Note 5)	(74.4		)	(50.0		)	(152.7		)	(263.9		)
Other, net	(8.0		)	(16.1		)	(8.0		)	(26.5		)
Consolidated income before taxes	$	4.8		$	1,260.5		$	1,445.8		$	1,321.7

Schedule of revenue from external customers and long-lived assets, by geographical areas



	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Geographic Information
Revenue—to unaffiliated customers ⁽¹⁾:
United States	$	3,602.0	$	3,323.9	$	6,756.7	$	6,257.5
Europe	1,090.7		963.6		2,125.9		1,860.6
Japan	664.3		627.5		1,220.1		1,150.3
Other foreign countries	998.2		909.3		1,952.5		1,784.2
Revenue	$	6,355.2	$	5,824.3	$	12,055.2	$	11,052.6

Numbers may not add due to rounding.

⁽¹⁾Revenue is attributed to the countries based on the location of the customer.

Basis of Presentation and Revenue Basis of Presentation and Revenue (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Disaggregation of Revenue [Line Items]
Revenue	$ 6,355.2	$ 5,824.3	$ 12,055.2	$ 11,052.6
Payment term, minimum (in days)			30 days
Payment term, maximum (in days)			75 days
Contract liabilities	315.7		$ 315.7		$ 335.2
Product
Disaggregation of Revenue [Line Items]
Revenue	5,899.6	5,529.8	11,241.1	10,517.7
Collaboration and Other Revenue
Disaggregation of Revenue [Line Items]
Revenue	455.6	294.5	814.1	534.9
Royalty
Disaggregation of Revenue [Line Items]
Revenue	$ 133.6	$ 35.0	$ 182.1	$ 68.8

Implementation of New Financial Accounting Pronouncements (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Jan. 01, 2018	Dec. 31, 2017
Concentration Risk [Line Items]
Accumulated other comprehensive loss	$ 6,108.7		$ 6,108.7			$ 5,718.6
Retained earnings	14,247.3		14,247.3			13,894.1
Revenue	6,355.2	$ 5,824.3	12,055.2	$ 11,052.6
Increase to deferred tax assets upon adoption	3,314.4		3,314.4			$ 1,166.4
Other, net	38.0	60.4	105.5	138.7
Cost of sales	1,702.7	1,571.7	3,274.0	2,919.6
Marketing, selling, and administrative	1,653.7	1,730.4	3,153.7	3,298.1
Research and development	$ 1,333.1	1,272.1	$ 2,510.0	2,530.4
Accounting Standards Update 2016-16
Concentration Risk [Line Items]
Retained earnings					$ 2,500.0
Increase to deferred tax assets upon adoption					2,500.0
Accounting Standards Update 2016-01
Concentration Risk [Line Items]
Accumulated other comprehensive loss					105.0
Retained earnings					105.0
Accounting Standards Update 2017-07
Concentration Risk [Line Items]
Other, net		64.3		127.5
Cost of sales		20.1		40.3
Marketing, selling, and administrative		23.0		46.0
Research and development		$ 21.2		$ 41.2
Difference between Revenue Guidance in Effect before and after Topic 606 \| Accounting Standards Update 2014-09
Concentration Risk [Line Items]
Retained earnings					$ 5.0

Acquisitions (Purchased Price) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Jan. 03, 2017
Business Acquisition [Line Items]
Goodwill	$ 4,333.1		$ 4,333.1		$ 4,370.1
Acquired in-process research and development	$ 1,624.5	$ 0.0	$ 1,624.5	$ 857.6
Boehringer Ingelheim Vetmedica, Inc.'s U.S. Vaccine Portfolio
Business Acquisition [Line Items]
Inventories						$ 108.6
Marketed products						297.0
Property and equipment						148.2
Other assets and liabilities - net						8.2
Total identifiable net assets						562.0
Goodwill						320.1
Total consideration transferred - net of cash acquired						$ 882.1

Acquisitions (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended					3 Months Ended		6 Months Ended
Acquisitions (Narrative) (Details) - USD ($) $ in Millions	Jul. 25, 2018	Jun. 30, 2018	Apr. 30, 2018	Mar. 31, 2017	Jan. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Business Acquisition [Line Items]
Acquired in-process research and development						$ 1,624.5	$ 0.0	$ 1,624.5	$ 857.6
Purchase of in-process research and development								$ 1,548.2	831.8
Boehringer Ingelheim Vetmedica, Inc.'s U.S. Vaccine Portfolio
Business Acquisition [Line Items]
All cash transaction					$ 882.1
Useful life (years)					10 years
Sigilon Therapeutics
Business Acquisition [Line Items]
Acquired in-process research and development			$ 66.9
Purchase of in-process research and development			$ 62.5
Aurka Pharma
Business Acquisition [Line Items]
Acquired in-process research and development		$ 81.8
Purchase of in-process research and development		81.3
Value of liabilities assumed		0.5
ARMO Biosciences, Inc.
Business Acquisition [Line Items]
Acquired in-process research and development		1,475.8
Purchase of in-process research and development		1,400.0
Value of liabilities assumed		$ 75.8
CoLucid Pharmaceuticals
Business Acquisition [Line Items]
Acquired in-process research and development				$ 857.6					$ 857.6
Purchase of in-process research and development				831.8
Value of liabilities assumed				$ 25.8
Subsequent Event \| Anima Biotech
Business Acquisition [Line Items]
Purchase of in-process research and development	$ 30.0

Collaborations and Other Arrangements (Details) - USD ($) $ in Millions	3 Months Ended					6 Months Ended		12 Months Ended	24 Months Ended	36 Months Ended	72 Months Ended
	Jun. 30, 2018	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 6,355.2			$ 5,824.3		$ 12,055.2	$ 11,052.6
Research and development	1,333.1			1,272.1		$ 2,510.0	2,530.4
Milestone Payments, Development and Regulatory, Capitalized, Cumulative \| Basaglar
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized									$ (250.0)
Milestone Payments, Development and Regulatory, Capitalized, Cumulative \| Trajenta
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized											$ 446.4
Milestone Payments, Development and Regulatory, Capitalized, Cumulative \| Jardiance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized										$ 299.5
Sales \| Erbitux
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement, rights and obligations (percentage)						38.00%
Royalty Agreement Terms \| Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement, rights and obligations (percentage)						20.00%
Research and Development Exp \| Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement, rights and obligations (percentage)						30.00%
Milestone Payments, Development and Regulatory, Expensed \| Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Research and development		$ 30.0						$ 55.0
Milestone Payments, Development and Regulatory \| Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized						$ 150.0
Milestone Payments, Development and Regulatory \| Tanezumab
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized						350.0
Milestone Payments, Sales-based \| Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized						150.0
Milestone Payments, Sales-based \| Tanezumab
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized						$ 1,230.0
Profit and Development and Marketing Share \| Effient
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement, rights and obligations (percentage)						50.00%
Human pharmaceutical products
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	5,563.2			5,039.4		$ 10,501.9	9,498.4
Human pharmaceutical products \| Product
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	141.1			134.4		263.3	265.7
Human pharmaceutical products \| Collaboration and Other Revenue
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	25.3			24.7		52.8	47.8
Human pharmaceutical products \| Basaglar
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	201.8			86.6		367.8	132.6
Human pharmaceutical products \| Erbitux
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	166.4			159.1		316.1	313.5
Human pharmaceutical products \| Effient
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	27.9			142.9		59.5	270.7
Human pharmaceutical products \| Trajenta
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	141.7			141.9		282.8	254.9
Human pharmaceutical products \| Jardiance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	147.2			103.2		298.2	177.1
Europe
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	1,090.7			963.6		2,125.9	1,860.6
Europe \| Milestone Payments, Development and Regulatory, Capitalized \| Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized					$ 65.0
Japan
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	664.3			627.5		1,220.1	1,150.3
Japan \| Milestone Payments, Development and Regulatory, Capitalized \| Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized			$ 15.0
U.S.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	3,602.0			3,323.9		6,756.7	6,257.5
U.S. \| Milestone Payments, Development and Regulatory, Capitalized \| Olumiant
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones (deferred) capitalized	100.0
U.S. \| Human pharmaceutical products
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	3,223.7			2,917.4		6,002.7	5,437.1
U.S. \| Human pharmaceutical products \| Basaglar
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	156.5			59.5		283.2	81.5
U.S. \| Human pharmaceutical products \| Erbitux
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	140.0			133.0		261.3	262.2
U.S. \| Human pharmaceutical products \| Effient
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	13.3			131.0		29.2	248.0
U.S. \| Human pharmaceutical products \| Trajenta
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	56.8			60.4		110.9	105.8
U.S. \| Human pharmaceutical products \| Jardiance
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Revenue	$ 85.6			$ 66.8		$ 180.6	$ 114.6

Asset Impairment, Restructuring, and Other Special Charges (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Restructuring Cost and Reserve [Line Items]
Severance	$ (27.3)	$ (1.0)	$ (19.9)	$ 167.6
Asset impairment and other special charges	74.4	50.0	152.7	263.9
Human pharmaceutical products
Restructuring Cost and Reserve [Line Items]
Severance	(24.6)	(1.7)	(24.7)	111.3
Animal health products
Restructuring Cost and Reserve [Line Items]
Severance	(2.7)	0.7	4.8	56.3
Asset impairment and other special charges - Animal health products	$ 101.7	$ 51.0	$ 172.6	$ 96.3

Financial Instruments (Effect of Risk-Management Instruments) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Designated as Hedging Instrument \| Effect from hedged fixed-rate debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Effect from hedged fixed-rate debt	$ (19.7)	$ 15.0	$ (74.5)	$ 7.5
Designated as Hedging Instrument \| Effect from interest rate contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Effect from interest rate contracts	19.7	(15.0)	74.5	(7.5)
Effective portion of losses on interest rate contracts reclassified from accumulated other comprehensive loss	3.7	3.7	7.3	7.4
Not Designated as Hedging Instrument \| Foreign currency exchange contracts
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Net losses on foreign currency exchange contracts not designated as hedging instruments	59.1	25.8	75.7	62.9
Net investment hedges
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)	208.5	(194.4)	100.8	(273.3)
Net investment hedges \| Cross-currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)	69.1	(51.5)	37.6	(57.6)
Cash Flow Hedging \| Interest Rate Swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Effective portion of risk-management instruments that was recognized in other comprehensive income (loss)	$ 0.0	$ 13.0	$ 0.0	$ 13.0

Financial Instruments (Risk Management Instruments) (Details) - USD ($) $ in Millions	Jun. 30, 2018	Dec. 31, 2017
Effect from interest rate contracts \| Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities		$ (0.2)
Effect from interest rate contracts \| Designated as Hedging Instrument \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities		0.0
Effect from interest rate contracts \| Designated as Hedging Instrument \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities		(0.2)
Effect from interest rate contracts \| Designated as Hedging Instrument \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities		0.0
Carrying Amount
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	$ (123.3)	(208.0)
Other noncurrent liabilities	(41.1)	(45.2)
Carrying Amount \| Effect from interest rate contracts \| Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables		0.8
Sundry		35.1
Other current liabilities	(4.2)
Other noncurrent liabilities	(45.5)	(10.5)
Carrying Amount \| Cross-currency interest rate swaps \| Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	21.2
Sundry	4.2
Other current liabilities	(20.5)	(33.4)
Other noncurrent liabilities		(26.0)
Carrying Amount \| Foreign currency exchange contracts \| Not Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	11.8	26.8
Other current liabilities	(9.6)	(36.0)
Estimate of Fair Value Measurement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	(123.3)	(208.0)
Other noncurrent liabilities	(41.1)	(45.2)
Estimate of Fair Value Measurement \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	0.0	0.0
Other noncurrent liabilities	0.0	0.0
Estimate of Fair Value Measurement \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	0.0	0.0
Other noncurrent liabilities	0.0	0.0
Estimate of Fair Value Measurement \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other current liabilities	(123.3)	(208.0)
Other noncurrent liabilities	(41.1)	(45.2)
Estimate of Fair Value Measurement \| Effect from interest rate contracts \| Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables		0.8
Sundry		35.1
Other current liabilities	(4.2)	(0.2)
Other noncurrent liabilities	(45.5)	(10.5)
Estimate of Fair Value Measurement \| Effect from interest rate contracts \| Designated as Hedging Instrument \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables		0.0
Sundry		0.0
Other current liabilities	0.0
Other noncurrent liabilities	0.0	0.0
Estimate of Fair Value Measurement \| Effect from interest rate contracts \| Designated as Hedging Instrument \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables		0.8
Sundry		35.1
Other current liabilities	(4.2)
Other noncurrent liabilities	(45.5)	(10.5)
Estimate of Fair Value Measurement \| Effect from interest rate contracts \| Designated as Hedging Instrument \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables		0.0
Sundry		0.0
Other current liabilities	0.0
Other noncurrent liabilities	0.0	0.0
Estimate of Fair Value Measurement \| Cross-currency interest rate swaps \| Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	21.2
Sundry	4.2
Other current liabilities	(20.5)	(33.4)
Other noncurrent liabilities		(26.0)
Estimate of Fair Value Measurement \| Cross-currency interest rate swaps \| Designated as Hedging Instrument \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	0.0
Sundry	0.0
Other current liabilities	0.0	0.0
Other noncurrent liabilities		0.0
Estimate of Fair Value Measurement \| Cross-currency interest rate swaps \| Designated as Hedging Instrument \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	21.2
Sundry	4.2
Other current liabilities	(20.5)	(33.4)
Other noncurrent liabilities		(26.0)
Estimate of Fair Value Measurement \| Cross-currency interest rate swaps \| Designated as Hedging Instrument \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	0.0
Sundry	0.0
Other current liabilities	0.0	0.0
Other noncurrent liabilities		0.0
Estimate of Fair Value Measurement \| Foreign currency exchange contracts \| Not Designated as Hedging Instrument
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	11.8	26.8
Other current liabilities	(9.6)	(36.0)
Estimate of Fair Value Measurement \| Foreign currency exchange contracts \| Not Designated as Hedging Instrument \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	0.0	0.0
Other current liabilities	0.0	0.0
Estimate of Fair Value Measurement \| Foreign currency exchange contracts \| Not Designated as Hedging Instrument \| Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	11.8	26.8
Other current liabilities	(9.6)	(36.0)
Estimate of Fair Value Measurement \| Foreign currency exchange contracts \| Not Designated as Hedging Instrument \| Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Other receivables	0.0	0.0
Other current liabilities	$ 0.0	$ 0.0

Financial Instruments (Contractual Maturities) (Details) $ in Millions	Jun. 30, 2018 USD ($)
Debt Securities Contractual Maturities
Total	$ 1,047.7
Less Than 1 Year	88.0
1-5 Years	656.8
6-10 Years	148.3
More Than 10 Years	$ 154.6

Financial Instruments (Unrealized gain and losses) (Details) - USD ($) $ in Millions	Jun. 30, 2018	Dec. 31, 2017
Fair Value Disclosures [Abstract]
Unrealized gross gains	$ 1.8	$ 184.7
Unrealized gross losses	25.2	47.5
Fair value of securities in an unrealized gain position	148.0	1,434.2
Fair value of securities in an unrealized loss position	$ 898.0	$ 4,692.8

Financial Instruments (Realized gain and losses) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Proceeds from sales		$ 959.0		$ 2,051.5
Realized gross gains on sales		22.2		73.9
Realized gross losses on sales		$ 1.1		$ 2.4
Adoption of ASU [Abstract]
Proceeds from sales	$ 4,953.8		$ 5,546.4
Realized gross gains on sales	5.6		7.7
Realized gross losses on sales	$ 47.4		$ 49.0

Financial Instruments (Narrative) (Details) € in Millions, ¥ in Millions, £ in Millions, SFr in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 EUR (€)	Jun. 30, 2018 CHF (SFr)	Jun. 30, 2018 GBP (£)	Jun. 30, 2018 USD ($)	Jun. 30, 2018 JPY (¥)	Dec. 31, 2017 USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Maximum remaining maturity of foreign currency derivatives			30 days
Description of derivative activity volume (percentage)					25.00%	25.00%	25.00%	25.00%	25.00%
Interest rate cash flow hedge gain (loss) to be reclassified during next 12 months								$ 14.9
Cash payment			$ 101.8
OTTI recognized	$ 0.0	$ 0.0	$ 0.0	$ 0.0
Available-for-sale, percentage of nonperforming assets (percentage)			60.00%
Amount of receivable derecognized								673.9		$ 723.2
Buy Us Dollar Sell Euro
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, notional amount								1,770.0
Derivative asset, notional amount \| €					€ 1,530
Buy Euro Sell Us Dollar
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, notional amount \| €					€ 1,080
Derivative asset, notional amount								1,260.0
Buy US dollar Sell Japanese Yen
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, notional amount								396.4
Derivative asset, notional amount \| ¥									¥ 43,670
Buy GBP Sell USD
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, notional amount \| SFr						SFr 159.5
Derivative asset, notional amount								160.6
Buy US dollar Sell British pound
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, notional amount								305.2
Derivative asset, notional amount \| £							£ 230.9
Foreign Currency Denominated Debt
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, including current portion								$ 3,400.0		$ 3,700.0
Equity Securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized gain (loss), net	$ 20.8		$ 38.6

Shareholders' Equity (Details) - USD ($)	3 Months Ended	6 Months Ended
Shareholders' Equity (Details) - USD ($)	Dec. 31, 2016	Jun. 30, 2018	Jun. 30, 2017	Oct. 31, 2013
Equity, Class of Treasury Stock [Line Items]
Purchases of common stock		$ 2,050,700,000	$ 199,900,000
2013 Share Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Shares repurchased		$ 2,050,000,000	$ 259,900,000
Shares repurchased (in shares)		25,800,000
Stock repurchase program, authorized amount (in shares)				$ 5,000,000,000
Purchases of common stock	$ 60,000,000
2018 Repurchase Program
Equity, Class of Treasury Stock [Line Items]
Shares repurchased (in shares)		0
Stock repurchase program, authorized amount (in shares)		$ 8,000,000,000

Income Taxes (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended		12 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Mar. 31, 2017	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2016
Operating Loss Carryforwards [Line Items]
Income taxes		$ 264.7	$ 252.5	$ 488.3	$ 424.5
Income before income taxes		4.8	1,260.5	1,445.8	1,321.7
Acquired in-process research and development		1,624.5	$ 0.0	$ 1,624.5	$ 857.6
Effective income tax rate, percentage				33.80%	32.10%
ARMO and AurKa
Operating Loss Carryforwards [Line Items]
Acquired in-process research and development		$ 1,560.0
CoLucid Pharmaceuticals
Operating Loss Carryforwards [Line Items]
Acquired in-process research and development	$ 857.6				$ 857.6
Tax Year 2013
Operating Loss Carryforwards [Line Items]
Tax year under examination						2013
Tax Year 2014
Operating Loss Carryforwards [Line Items]
Tax year under examination						2014
Tax Year 2015
Operating Loss Carryforwards [Line Items]
Tax year under examination						2015

Retirement Benefits (Narrative) (Details) $ in Millions	6 Months Ended
Retirement Benefits (Narrative) (Details) $ in Millions	Jun. 30, 2018 USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
Pension contributions	$ 25
Estimated future employer contributions in current fiscal year	$ 30

Retirement Benefits (Components of Net Periodic Benefit Cost) (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Defined Benefit Pension Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 77.7	$ 86.7	$ 158.1	$ 165.6
Interest cost	112.0	103.2	224.6	205.6
Expected return on plan assets	(211.2)	(195.3)	(423.7)	(389.3)
Amortization of prior service cost	1.3	1.5	2.5	2.9
Recognized actuarial loss	91.6	70.4	182.0	143.1
Net periodic benefit cost	71.4	66.5	143.5	127.9
Retiree Health Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Service cost	10.9	12.0	21.6	23.2
Interest cost	13.5	13.4	27.4	26.4
Expected return on plan assets	(43.9)	(40.1)	(87.8)	(80.4)
Amortization of prior service cost	(20.4)	(22.5)	(40.9)	(45.0)
Recognized actuarial loss	2.2	5.1	4.6	9.2
Net periodic benefit cost	$ (37.7)	$ (32.1)	$ (75.1)	$ (66.6)

Contingencies (Details) R$ in Millions, $ in Millions	1 Months Ended		6 Months Ended
Contingencies (Details) R$ in Millions, $ in Millions	Jun. 30, 2018 case company patent demand application	Aug. 31, 2015 plaintiff	Jun. 30, 2018 BRL (R$) individual company patent lawsuit plaintiff demand defendant application	Jun. 30, 2018 USD ($) individual company patent lawsuit plaintiff demand defendant application	Feb. 28, 2017 company demand
U.S. \| Alimta
Loss Contingency [Line Items]
Number of new application \| application	10		10	10
Number of defendants \| defendant			2	2
Number of companies \| company	5		5	5
Dr Reddy's Lab
Loss Contingency [Line Items]
Number of cases ruled in favor \| case	2
Japanese Administrative Proceedings
Loss Contingency [Line Items]
Number of companies \| company					3
Number of demands \| demand	3		3	3
Number of patents \| patent	2		2	2
Number of demands resumed \| demand					1
Number of demands remaining \| demand					2
Product Liability Litigation \| Cymbalta
Loss Contingency [Line Items]
Number of lawsuits \| lawsuit			140	140
Number of plaintiffs \| plaintiff		4	1,470	1,470
Product Liability Litigation \| California \| Cymbalta
Loss Contingency [Line Items]
Number of lawsuits \| individual			40	40
Employee Litigation \| Brazil
Loss Contingency [Line Items]
Number of lawsuits \| lawsuit			30	30
Damages awarded, value			R$ 1,000	$ 260
Number of Individuals \| individual			105	105
Employee Litigation Ruling in April 2018 \| Brazil
Loss Contingency [Line Items]
Damages awarded, value			R$ 500	$ 130
Agri Stats, Inc.
Loss Contingency [Line Items]
Number of lawsuits \| lawsuit			15	15
Plaintiff Appealing Decision of Court \| Employee Litigation \| Brazil
Loss Contingency [Line Items]
Number of Individuals \| individual			305	305

Other Comprehensive Income (Loss) (AOCI) (Details) - USD ($)
$ in Millions

3 Months Ended

6 Months Ended

Jun. 30, 2018

Jun. 30, 2017

Jun. 30, 2018

Jun. 30, 2017

Dec. 31, 2017

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Other comprehensive income (loss) before reclassifications

$ 11,667.9

$ (700.4)

$ 257.5

(375.8)

$ 447.4

Net amount reclassified from accumulated other comprehensive loss

29.2

27.3

90.9

36.1

^[1]

(671.2)

284.8

(284.9)

483.5

Accumulated Other Comprehensive Loss

11,620.8

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Reclassification due to adoption of new accounting standard

(5,437.5)

(5,027.1)

(5,694.9)

(5,225.8)

$ (128.9)

Foreign Currency Translation Gains (Losses)

(6,108.7)

(4,742.3)

(6,108.7)

(4,742.3)

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Reclassification due to adoption of new accounting standard

(850.6)

(1,648.7)

(1,233.4)

(1,867.3)

0.0

Other comprehensive income (loss) before reclassifications

(820.9)

299.3

(438.1)

517.9

Net amount reclassified from accumulated other comprehensive loss

0.0

(820.9)

299.3

(438.1)

517.9

Unrealized gains/losses on available-for-sale securities

(1,671.5)

(1,349.4)

(1,671.5)

(1,349.4)

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Reclassification due to adoption of new accounting standard

(51.0)

179.4

113.5

224.0

(128.9)

Other comprehensive income (loss) before reclassifications

65.9

(12.5)

29.9

(24.3)

Net amount reclassified from accumulated other comprehensive loss

(33.0)

(13.7)

(32.6)

(46.5)

32.9

(26.2)

(2.7)

(70.8)

Defined Benefit Pension and Retiree Health Benefit Plans

(18.1)

153.2

(18.1)

153.2

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Reclassification due to adoption of new accounting standard

(4,304.4)

(3,349.4)

(4,340.7)

(3,371.6)

0.0

Other comprehensive income (loss) before reclassifications

54.5

(37.7)

32.4

(54.6)

Net amount reclassified from accumulated other comprehensive loss

59.3

38.6

117.7

77.7

113.8

0.9

150.1

23.1

Effective Portion of Cash Flow Hedges

(4,190.6)

(3,348.5)

(4,190.6)

(3,348.5)

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Reclassification due to adoption of new accounting standard

(231.5)

(208.4)

(234.3)

(210.9)

0.0

Other comprehensive income (loss) before reclassifications

0.1

8.4

0.0

8.4

Net amount reclassified from accumulated other comprehensive loss

2.9

2.4

5.8

4.9

3.0

10.8

5.8

13.3

AOCI Attributable to Parent

$ (228.5)

(197.6)

(228.5)

(197.6)

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Reclassification due to adoption of new accounting standard

(5,718.6)

(5,274.0)

(104.8)

AOCI Attributable to Noncontrolling Interest

(4,774.9)

AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]

Reclassification due to adoption of new accounting standard

$ 23.7

48.2

$ (24.1)